| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7741269 | ASTRAZENECA AB | Exendins and exendin agonists for weight reduction and obesity |
Jan, 2018
(6 years ago) | |
| US6956026 | ASTRAZENECA AB | Use of exendins for the reduction of food intake |
Jan, 2018
(6 years ago) | |
| US6872700 | ASTRAZENECA AB | Methods for glucagon suppression |
Jan, 2020
(4 years ago) | |
| US6667061 | ASTRAZENECA AB | Preparation of injectable suspensions having improved injectability |
May, 2020
(3 years ago) | |
| US6479065 | ASTRAZENECA AB | Process for the preparation of polymer-based sustained release compositions |
Aug, 2020
(3 years ago) | |
| US9198925 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct, 2020
(3 years ago) | |
| US6414126 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US6936590 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2020
(3 years ago) | |
| US7223440 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Aug, 2021
(2 years ago) | |
|
US7223440 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Mar, 2022
(2 years ago) | |
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(1 year, 6 months ago) | |
|
US6824822 (Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(1 year, 20 days ago) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(13 days ago) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(13 days ago) | |
|
US9238076 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
|
US7563871 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(5 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(11 months from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(1 year, 2 months from now) | |
|
US8431685 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7612176 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US8461105 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(1 year, 5 months from now) | |
|
US7456254 (Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(1 year, 8 months from now) | |
|
US6515117 (Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(1 year, 11 months from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(2 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(2 years from now) | |
|
US8906851 (Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(2 years from now) | |
|
US8329648 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
|
US9884092 (Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(3 years from now) | |
|
US8501698 (Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(3 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(3 years from now) | |
|
US8361972 (Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(4 years from now) | |
| US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(6 years from now) | |
|
US8895033 (Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(6 years from now) | |
Bydureon Bcise is owned by Astrazeneca Ab.
Bydureon Bcise contains Exenatide Synthetic.
Bydureon Bcise has a total of 38 drug patents out of which 14 drug patents have expired.
Expired drug patents of Bydureon Bcise are:
- US7741269
- US6956026
- US6872700
- US6667061
- US6479065
- US9198925
- US6414126
- US6936590
- US7223440
- US7223440*PED
- US6824822
- US6824822*PED
- US9238076
- US7563871
Bydureon Bcise was authorised for market use on 20 October, 2017.
Bydureon Bcise is available in suspension, extended release;subcutaneous dosage forms.
Bydureon Bcise can be used as reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea, improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise, reductions in body weight are observed with exenatide, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin, as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication.
The generics of Bydureon Bcise are possible to be released after 04 April, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jul 22, 2024 |
| Pediatric Exclusivity(PED) | Jan 22, 2025 |
| M(M-240) | Feb 15, 2022 |
| New Product(NP) | Oct 20, 2020 |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Market Authorisation Date: 20 October, 2017
Treatment: Reductions in body weight are observed with exenatide; Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4; As an adjunct to diet and exercise to imp...
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON BCISE family patents
